Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zoetis Inc. (ZTS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zoetis, described as the world’s leading animal health company, uses filings such as Form 8-K to report material events related to its operations, financing activities, governance and shareholder returns.
Recent 8-K filings detail several types of information. Zoetis has reported the completion of a private offering of 0.25% Convertible Senior Notes due 2029, including the terms of the notes, their conversion features, optional redemption provisions and related capped call transactions. Other filings describe the issuance of senior notes due 2028 and 2035 under an existing indenture, as well as a revolving credit agreement that provides a senior unsecured revolving credit facility and replaces a prior credit agreement.
Filings also cover corporate actions affecting shareholders, such as declarations of cash dividends on Zoetis common stock and the use of proceeds from financing transactions to repurchase shares under an existing share repurchase program. Additional 8-Ks report quarterly financial results, guidance updates, and investor presentations, including an Innovation Webcast that outlines the company’s pipeline and strategic approach to addressing unmet medical needs in animals.
Through this page, users can review how Zoetis discloses information about its NYSE-listed common stock, debt obligations, credit facilities and board-level decisions. Stock Titan’s platform associates these filings with AI-powered tools that summarize key terms and highlight items such as note covenants, leverage provisions, dividend declarations and event-driven disclosures, helping readers interpret lengthy documents more efficiently.
Norden Gregory reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Gregory Norden reported an equity award of 1,936 restricted stock units (RSUs) on February 18, 2026, granted under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan. Each RSU represents a contingent right to receive one share of Zoetis common stock and will vest on the first anniversary of the grant date, subject to his continued service and certain earlier-vesting events.
MCCALLISTER MICHAEL B reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Michael B. McCallister received an equity award of 1,936 restricted stock units on February 18, 2026. The award was granted under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan and includes related dividend equivalent units. Each unit represents a right to receive one share of Zoetis common stock. These RSUs vest and settle in shares on the first anniversary of the grant date, February 18, 2026, if he continues in service, with provisions for earlier vesting upon certain specified events. McCallister also reports 1,619.3325 previously granted RSUs that are scheduled to vest and settle on February 19, 2025, subject to similar service and early-vesting conditions.
PARENT LOUISE M reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Louise M. Parent reported an equity award of 1,936 restricted stock units (RSUs). The RSUs were granted at a price of $0.00 per unit and increase her directly held RSU balance to 1,936 units from this grant.
Each RSU represents a contingent right to receive one share of Zoetis common stock. According to the terms, these RSUs are scheduled to vest and be settled in shares on the first anniversary of the grant date, February 18, 2026, subject to her continued service and certain earlier-vesting events.
The filing also shows a separate RSU holding line with 1,619.3325 RSUs, which relates to a prior grant scheduled to vest on February 19, 2025 under similar continued-service conditions.
Stetter Mark reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Mark Stetter received a grant of 1,936 restricted stock units (RSUs) of Zoetis common stock. Each RSU represents the right to receive one Zoetis share and is issued at no cash cost, vesting after one year of continued service, subject to certain early-vesting events.
Lagano Roxanne reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Roxanne Lagano reported equity awards on February 18, 2026. She received 3,664 restricted stock units and 14,499 stock options for Zoetis common stock, granted under the company’s equity and incentive plan.
Each RSU represents a right to one Zoetis share and is scheduled to vest in three equal installments on the first, second, and third anniversaries of the grant date, subject to continued service and certain earlier-vesting events. The stock options also vest in three equal annual installments and expire on the tenth anniversary of the grant date.
Zoetis Inc. director Antoinette Renee Leatherberry reported an equity award in the form of restricted stock units (RSUs). She acquired 1,936 RSUs at a stated price of $0.00 per unit, bringing this award to 1,936 RSUs. Each RSU represents a contingent right to receive one share of Zoetis common stock. According to the footnotes, these RSUs will vest and be settled in shares on the first anniversary of the grant date, February 18, 2026, subject to her continued service and certain earlier-vesting events. A separate line shows 1,619.3325 RSUs outstanding from a prior grant that is scheduled to vest and settle on February 19, 2025, under similar continued-service conditions.
Reed Willie M reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Willie M. Reed reported an equity award of 1,936 restricted stock units (RSUs) granted on February 18, 2026 at a price of $0.00 per unit. Each RSU represents a contingent right to receive one share of Zoetis common stock and was granted under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan, including related dividend-equivalent units. According to the terms, these RSUs will vest and be settled in Zoetis common shares on the first anniversary of the grant date, February 18, 2026, subject to Reed’s continued service and certain earlier-vesting events.
Broadhurst Vanessa reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Vanessa Broadhurst received a grant of 1,936 restricted stock units (RSUs) on February 18, 2026 under the company’s equity and incentive plan. Each RSU represents a contingent right to one Zoetis common share and will vest on the first anniversary of the grant, subject to continued service and certain earlier-vesting events.
Hattersley Gavin reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. director Gavin Hattersley reported an equity award of 1,936 restricted stock units (RSUs) on February 18, 2026 at a stated price of $0.00 per unit, reflecting a grant under the company’s Amended and Restated 2013 Equity and Incentive Plan.
Each RSU represents a contingent right to receive one share of Zoetis common stock and will vest and be settled on the first anniversary of the grant date, February 18, 2026, subject to his continued service and certain earlier vesting conditions. Following these transactions, Hattersley directly holds RSUs including 1,619.3325 units from a prior grant scheduled to vest on February 19, 2025.
Driscoll Rimma reported acquisition or exercise transactions in this Form 4 filing.
Zoetis Inc. Executive Vice President Rimma Driscoll reported equity awards under the company’s Amended and Restated 2013 Equity and Incentive Plan. On February 18, 2026, she received 2,323 restricted stock units (RSUs) and 9,191 stock options, each RSU representing one share of common stock.
One-third of the new RSUs and one-third of the options vest on each of the first, second and third anniversaries of the grant date, subject to continued service and certain earlier‑vesting events. Each option allows her to buy Zoetis common stock and expires on the tenth anniversary of its grant.